














Scottish Drug Deaths Taskforce: 
One Year Report  
 
This report details the work and achievements of the Drug Deaths 






It is a year since the Ministerial Drug Deaths Taskforce was formed. The reason for 
the Taskforce was clear, the shocking escalation in the rise of drug related deaths 
over the last five years required urgent attention. The pain of loss being suffered by 
families and within communities was, and is, palpable. Urgent and sustained action 
was required to prevent this unnecessary loss. 
 
The Taskforce approach has been one of evidence into action. Year one was our 
Evidence Review and Immediate Response Phase.  We initiated an immediate 
response consultation to capture the views of the wider community. There was areas 
where the evidence was already known and clear.  From this we developed our six 
evidence based strategies that was shared with local areas to provide a framework 
for their local response. For example the distribution of naloxone, the need for rapid 
access to good quality treatment and the importance of rapid out-reach to people 
who experience a non-fatal overdose. 
 
There are gaps in evidence that we seek to fill through a research fund and new 
approaches to address the multiple and complex needs of some people, that we feel 
are part of the unique Scottish context. This is being addressed through an 
innovation fund. Year Two of the Taskforce will be the Action and Review Phase 
when work implemented in phase one will progress with ongoing monitoring and 
evaluation. 
 
When corona virus arrived and the resulting lockdown arrangements were being put 
in place it was clear the work of the Taskforce had to adjust to prevent harm and 
further risk to the very people we were trying to help. Many of our members were 
pulled into corona virus emergency management. Despite this we were able to 
continue to meet virtually and make recommendations to minimise harm. Corona 
virus helped some aspects of our work such as increasing access to naloxone. It 
also helped development of a public health surveillance system so that we can 
monitor overdose and drug related deaths to rapidly detect the impact of changes to 
treatment delivery during this time. 
 
We really regret that the engagement component of our work was scaled back due 
to Covid restrictions. We had planned a meeting in Ayrshire in March as well as a 
conversation café event in June in Lanarkshire. However we are now reigniting this 
work to continue to build participation and access wider lived and living experience, 
albeit in a slightly different format. The importance of working in partnership with 
communities across the country is key to being able to drive down drug deaths and 
prevent further pain for families and friends of those who suffer an unnecessary 
death. 
   
 
Professor Catriona Matheson Joe FitzPatrick 





DRUG DEATHS TASKFORCE – INTERIM REPORT 
 
Background 
The Drug Deaths Taskforce (DDTF) was set up in June 2019 in acknowledgment of 
the rising number of drug related deaths (DRDs) in Scotland. In July 2019, National 
Records Scotland published their annual DRD statistics which showed that Scotland 
had recorded 1,187 drug related deaths in 2018, 253 (27%) more than in 2017 and 
the highest number ever recorded. 
 
Chaired by Professor Catriona Matheson, with Neil Richardson OBE as Vice Chair, 
the DDTF is made up of individuals each of whom were specifically asked to be on 
the group either in a personal capacity or on behalf of the organisations they 
represent (a full membership list of the DDTF is available at Annex A). This 
membership was also selected for their ability to oversee any change in their 
respective organisations which may be required to improve this situation.  
 
An overview of the DDTF can be found here - 
https://drugdeathstaskforce.scot/about-the-taskforce/. This summarises what the 
group were asked specifically to do. However, the Minister for Public Health, Sport 
and Wellbeing had been clear in his letter of invitation to members that the purpose 
of the group was to examine how changes could be made in practice and in law to 
reduce the level of harm and death being experienced by people who use drugs, to 
tackle the rising number of drug deaths in Scotland.  
 
Meetings 
The DDTF has now met 7 times since its first meeting in September 2019. A list of 
meetings (dates and locations) is included at Annex B for information while copies of 
all minutes can be found on the DDTF website (https://drugdeathstaskforce.scot). 
 
In addition, the sub-groups of the DDTF have also been meeting on a regular basis 
since their formation at that initial September meeting. Details of the membership of 
each group can be found in Annex A, while a list of their meeting dates is included in 
Annex B for information. 
 
At the first meeting of the DDTF in September 2019 a number of presentations were 
made setting out the scale of the problem and detailing some of the current 
strategies and approaches being used to address drug deaths. In addition sub-
groups of the DDTF were established to specifically focus on specific topics and to 
take forward work in those areas. 
 
These sub-groups are: Public Health Surveillance (to advise on how an effective 
public health surveillance system can be established to support whole system, public 
health action to prevent and address harms from drug use); Medication Assisted 
Treatment (MAT), to define national standards for the consistent delivery of ‘no 
barrier,’ rapid access to treatment (MAT Standards) in Scotland1; Multiple Complex 
Needs (to explore the wider complex needs of people most at risk of drug related 
 
1 The term Medication Assisted Treatment (MAT) was adopted by the sub-group in place of the 
commonly used Opioid Substitute Therapy as it was agreed by the group that the focus of the group 
should be on medication assisted treatment which refers to the use of medication, such as opioids, 




death and make recommendations on how services and systems should be 
improved to address these needs); and Criminal Justice and the Law (to improve 
and accelerate access into health and social care services from the criminal justice 
system within the existing law).  
 
The importance of addressing stigma was also considered and the development of a 
drug checking pilot endorsed.  Recommendations for change in a number of areas 
were made at that first meeting and these were followed by a consultation exercise, 
prior to the second meeting, to identify possible options to deliver an immediate 
response on drug related deaths. 
 
This consultation work, and a review of existing evidence, led to 6 areas being 
identified for immediate prioritisation. These are:  
1. Targeted distribution of naloxone 
2. Implement immediate response pathway for non-fatal overdose 
3. Optimise the use of Medication-Assisted Treatment 
4. Target the people most at risk 
5. Optimise Public Health Surveillance 
6. Ensure equivalence of support for people in the Criminal Justice System 
 
The third meeting of the taskforce took place in Dundee where it heard from 
members of the Dundee Drugs Commission (DDC), alongside representatives from 
local drug and alcohol treatment providers, Dundee ADP, Dundee Council and 
others, on the changes that had been implemented there as a result of the 
recommendations from the DDC. In addition, colleagues from NRS presented at that 
meeting on how the annual statistics are produced and how the current delays to 
toxicology reporting impacts on their ability to publish these statistics on time. 
 
Further meetings of the taskforce were initially interrupted by the outbreak of the 
COVID-19 pandemic, particularly as numerous taskforce members found themselves 
having to dedicate more time to their main jobs as the country reacted to a separate 
public health emergency. However, keen that the momentum that had been built up 
by the DDTF didn’t disappear, the Chair decided that shorter and more focussed 
DDTF meetings should still take place. This led to 4 meetings taking place between 
April and end July. 
 
The initial focus of these meetings was around the immediate response to the 
pandemic and the effect this had had on people who use drugs.  
 
Further meetings kept that same focus on the impact of the pandemic and what 
could be done in response, with regards DRDs. Following the allocation of funding 
from the Scottish Government to the DDTF to support local and national projects to 
reduce DRDs, there was discussion at these meetings about the processes through 
which this money would be distributed. More information about the funds which the 
DDTF oversees can be found on page 20. 
 
Achievements 
While the majority of the work of the DDTF is being taken forward by its sub-groups, 
the DDTF as a whole has implemented a number of changes in the times since its 




Drug Partnerships and drug and alcohol treatment services. Some of the 
achievements from this early stage of the DDTF include: 
 
Winter shelters and naloxone – Following the second meeting of the DDTF 
(November 2019), the group recommended that making additional naloxone 
provision available to those individuals accessing homelessness services throughout 
the country, particularly in the winter months, could have a significant impact on 
reducing harms at this time. Subsequently the Minister for Public Health wrote to all 
NHS Board Naloxone Leads asking them to make contact with those organisations 
running homelessness services in each area to ensure that all accommodation and 
support services likely to come into contact with people at risk of opioid overdose 
had naloxone on site, and staff and volunteers who were trained to respond and 
administer it if required. In addition, he asked that they take active steps to have staff 
(or peers, if using the peer supply scheme) in attendance at those services who 
would be able to make supplies available for individuals to take away if needed. 
 
Preventing drug related deaths in Scotland: emergency response strategies – 
In January 2020 the DDTF published a document setting out six key evidence-based 
strategies for preventing drug related deaths highlighting that these strategies should 
form the basis of national and local responses as quickly as possible. 
This paper was sent to all Alcohol and Drug Partnerships (ADPs) along with a 
request for them to provide benchmark information on what work was currently being 
undertaken in relation to each of these. This has also helped to inform the allocation 
of additional funding being made available to ADPs (more information is available on 
this on page 20). 
 
Scottish Ambulance Service (SAS) and naloxone – After discussion at the 
second meeting of the DDTF about the role that SAS could take in working to reduce 
DRDs, the DDTF agreed to directly fund a 3 month trial with SAS which would 
enable paramedics in Glasgow (the pilot site) to give patients who have had a non-
fatal overdose a naloxone kit to take away, along with training provided on how to 
use it. This pilot has now completed and SAS colleagues are working to roll this 
initiative out nationally.  
 
Police and naloxone – Having Police Scotland representation on the DDTF has 
been hugely beneficial, not least in making progress around police carriage of 
naloxone, a topic which has been discussed for a number of years with little 
progress. Following on-going disquiet from the Scottish Police Federation (SPF) on 
this subject (the DDTF wrote to the SPF responding on some points of opposition 
raised by them in a statement), agreement has now been reached with Police 
Scotland around the development of proposals for a pilot which would allow officers 
to carry naloxone. This is a significant step forward and one which could potentially 
lead to Scotland being a leader in the UK in terms of their police involvement.   
 
Stigma strategy – The importance and value in tackling the prevailing stigma 
around people who use drugs was identified and discussed by the DDTF at their 
very first meeting. This led to the DDTF requesting colleagues from Scottish 
Recovery Consortium, Scottish Drugs Forum and Scottish Families Affected by 
Alcohol and Drugs to produce a strategy to reduce the stigma associated with drug 
use and accessing drug treatment services. This has now been completed (and has 





agreement from the Scottish Government to implement the recommendations. 
 
Other work which has been agreed but which is still being progressed includes:  
supporting a proposal for a pilot of ‘assertive outreach’ in Glasgow which will target 
the most vulnerable people, providing out of hours care for those who have been 
difficult to get into support services which could save lives; and a project to work with 
family members who are concerned that a loved one is at risk of a drug related 
death. Support for the development of a proposal for a drug checking service in 
Scotland has also been confirmed and will progress as soon as Covid-19 allows.  
 
COVID-19 
The arrival of the COVID-19 pandemic added a new and unknown variable to the 
problem of addressing rising DRDs in Scotland. Despite not being able to meet in the 
early stages of the pandemic, the DDTF very quickly published a statement 
highlighting those areas which they would prioritise to mitigate any potential rise in 
DRDs as an indirect result of Covid19 (these were: naloxone availability and 
provision; the need for stability around the provision of MAT; and the need for 
ongoing public health surveillance to provide good quality information).   
 
When the DDTF did meet virtually it produced a list of recommendations for the 
Scottish Government to implement which would mitigate the harms from COVID-19-
related service disruption and decline. Details of these recommendations can be 
found here ( https://drugdeathstaskforce.scot/news-
information/publications/examples-of-innovation/covid-19-pandemic-the-edinburgh-
response-by-homelessness-drug-alcohol-services/ ).  
 
These recommendations were largely delivered and were particularly appreciated by 
the sector, not least the top recommendation for the Minister for Public Health, along 
with the Chief Medical officer, to write out to Chief Executives of Health Boards and 
the Chief Officers of Health and Social Care Partnerships to ensure that they 
maintained service-level provision for drug and alcohol services.  
 
This was also followed by a letter from the Minister for Public Health, the Chief 
Pharmaceutical Officer and the Chair of the DDTF to the Directors of Pharmacy and 
Community Pharmacy Scotland regarding the continued delivery of opioid substitute 
therapy during the pandemic.  
 
The need for further information about the impact of the pandemic on those with 
problem substance use also led to additional work being undertaken by the Public 
Health Surveillance sub-group as they sought to create a specific, short-term 
monitoring and surveillance approach to understanding the impact of COVID-19 on 
drug services, looking specifically at: drug deaths; service activity; and naloxone 
availability. 
 
Due to the disruption caused by the COVID-19 pandemic, drug treatment services 
who are lawfully permitted to distribute naloxone were restricted in their ability to do 
so. Following discussion at DDTF meetings, and an approach from Scottish 
Government officials, the Lord Advocate authorised the publication of a statement of 
prosecution policy which makes clear that for the period of disruption caused by 




non-drug treatment services registered with the Scottish Government, who distribute 
naloxone for use in an emergency to save a life. This is contingent on sufficient 
training on the use of naloxone and basic first aid information being provided 
alongside the medication. 
While the statement does make clear that this policy is only in place for the for the 
period of disruption caused by the pandemic, it has allowed for a range of new 
organisations to be able to distribute take home naloxone (“THN”) in a variety of 
ways (for example allowing hostels and homeless shelters to supply THN kits on to 
others for their possible future use, or through the use of an online ‘click and deliver’ 
system) during the course of the pandemic.  
Scottish Government officials are working closely with Public Health Scotland 
colleagues to monitor the effect of this change on the numbers of THN kits in the 
community to gather evidence in relation to the success of this scheme. In addition, 
conversations are ongoing with UK Government colleagues about a potential change 





DRUG DEATH TASKFORCE SUB-GROUP – INTERIM REPORTS 
 
Public Health Surveillance 
 
Purpose 
The World Health Organisation describes public health surveillance as: 
 
“The continuous, systematic collection, analysis and interpretation of health-related 
data needed for the planning, implementation, and evaluation of public health 
practice. Such surveillance can: 
• serve as an early warning system for impending public health emergencies; 
• document the impact of an intervention, or track progress towards specified 
goals; and 
• monitor and clarify the epidemiology of health problems, to allow priorities to be 
set and to inform public health policy and strategies” 2  
 
Put simply, public health surveillance is the way in which we create intelligence 
which informs essential public health action to address a public health concern.  
  
The DDTF’s sub-group on public health surveillance was given the remit to set out a 
clear statement of what is needed for a Public Health Surveillance System (PHSS) in 
Scotland. This will include how it can be established and how it will function to 
support whole system, public health action to prevent and address harms from drug 
use. In creating the PHSS, the sub-group will: 
• review what is already in place that can be used to underpin the PHSS;  
• what else will be needed to create a national PHSS; and  
• advise on the necessary steps and infrastructure to make it happen in an efficient 
and sustainable way.  
 
Activities in Year One 
The work of the sub-group during the first year of the task force can be separated 
into work undertaken prior to the national COVID-19 pandemic response was 
initiated and that which has occurred as a part of the COVID-19 response.  
 
Pre-COVID-19, the sub-group had: 
• developed the formal Terms of Reference for the sub-group and agreed these 
with the Task Force;  
• established a set of short and medium term deliverables for the work of sub-
group; and  
• secured the necessary resources for the work to be undertaken in collaboration 
with existing public health teams and drug services teams across Scotland. This 
has included the creation of a new functional team within Public Health Scotland, 
which came into existence in April 2020.  
 
As the year progressed, the sub-group has progressed work against its Phase 1 
deliverables. These focused on:  
 
2 WHO, Public Health Surveillance (see: https://www.who.int/topics/public_health_surveillance/en/, 




1. mapping of those stakeholders who see themselves as part of the whole system 
in relation preventing and address drug related harms; 
2. understanding those existing activities that should feed into work developing the 
PHSS on a national and local basis; and 
3. advising on what is possible now, within confines of the (then) currently available 
data to provide better intelligence on drug related harms.  
 
Linking to the early participation work detailed below the sub-group has also started 
to explore how best it can ensure that the voice of those with lived experience are 
captured in its work. 
 
With the establishment of the national COVID-19 pandemic response, the sub-group 
has reoriented its work.  
 
Firstly, it has accelerated its work on deliverable 3 to create a specific, short-term 
monitoring and surveillance approach to understanding the impact of COVID-19 on 
drug services. This has emphasized: drug deaths; service activity; and naloxone 
availability. This has been linked to UK-wide COVID-19 monitoring. This data is now 
available as management data at national level and is shared on a limited basis to 
those involved with local service planning. Work is currently underway to use 
Scottish Ambulance Service and critical care data on non-fatal overdoses as a 
means of understanding impact. How this data can be more publically available is 
also being explored.  
 
Secondly, the sub-group has been working with Scottish Government and Alcohol 
and Drug Partnership colleagues to develop a way in which it can use work on 
deliverable 1 that seeks to establish stakeholder expectations for work around 
surveillance in a way that helps to provide surveillance data for local COVID-19 
responses. Despite the restrictions created by the pandemic there remains a 
commitment to widen participation and input from experts by experience to support 
the development process.  Through the participation work to date, community 
members have expressed a keen interest to both challenge and help articulate the 
data and system needs.   
 
 
Priorities going forward (next 3,6,12 months) 
As the pandemic response develops, and Scotland moves through the phases of the 
route map out of lockdown, the sub-group will seek to progress the medium and longer 
term deliverables agreed with the Taskforce. It is acknowledged that will have to be 
progressed alongside the wider programme of system and service remobilization.   
 
At this stage, and assuming that we are able to we anticipate that our priorities will be 
to for the next: 
• Three months: 
o establishing the more detailed understanding of the aims and aspirations for the 
PHSS across the whole system; and  
o creating a statement of best practice for the public health surveillance of 
substance misuse from the UK and internationally.  
 




o building on the experiences from surveillance during the pandemic, creating the 
initial scope and function statement for a preliminary PHSS based on existing 
resources, current data collection, and information flows; and 
o setting out a plan for how that can be implemented in a sustainable manner. 
 
• Twelve months: 
o set out the detailed scope and function statement for the full PHSS, identifying 
necessary development in human and capital resources, future data collection 
and information flows, and procedures for analytical approaches, reporting, and 
dissemination; 
o develop the implementation plan for how the preliminary PHSS can be 
enhanced to create the full PHSS; and  
o make recommendations regarding any necessary changes in agency guidance 



































Multiple and Complex Needs  
 
Purpose  
The purpose of the multiple and complex needs group is to explore the wider 
complex needs of people most at risk of drug related death and make 
recommendations on how services and systems should be improved to address 
these needs. 
 
This work includes examining existing evidence and research in this area, reviewing 
the current policy landscape and examining the implementation of existing policy 
recommendations and commitments, identifying knowledge gaps and areas requiring 
further research or action and making recommendations to the full Taskforce. 
 
The work of the group will inform and complement the work of the Scottish 
Government in the development of the Inclusive Scotland Fund which is intended to 
address multiple and complex needs at the structural and service delivery level. 
The multiple and complex needs group has focused its work to complement the work 
of the Criminal Justice and Health sub-group and the Medication Assisted Treatment 
sub-group. 
 
Activities in Year One  
The group has taken a person-centred approach to this inquiry and has focused on 
the provision and accessibility of services for people with multiple and complex 
needs who are at risk of drug related death. Multiple and complex needs by their 
very nature cover a wide range of services and policy areas and whilst the group is 
taking a whole systems approach to its work, the following areas have been 
identified to be of specific importance: Drug treatment services and assertive 
outreach; primary healthcare; mental health services; housing and homelessness 
services; services for women; advocacy; welfare, and employability services. 
We are also aware of the links with issues pertaining to criminal justice. 
There is also an essential need to highlight the key role of family members and the 
essential support available from Recovery Communities. 
 
Actions from the group will work on the basis of maximising informed choice where 
people are able to access a range of care options and are empowered to make 
informed choices that meet their needs at any given time. Innovations and actions 
the group makes and takes will build on the principle of ‘no wrong door’. The group 
will ensure that the voice of lived and living experience is incorporated into its work. 
 
The group’s focus has been to request a rapid review of evidence regarding drug 
related deaths among individuals with multiple and complex needs. 
The following questions were addressed in carrying out the synthesis of relevant 
documents: 
• What are the multiple and complex needs of people who use drugs in 
Scotland and how do they increase the risk of harms and specifically drug 
related death? 
• What barriers do people who use drugs with multiple and complex needs face 
in accessing health care? 
• Which models of support / interventions are most appropriate for supporting 




• What changes in policy and practice can reduce drug related harms, including 
risk of death for individuals with multiple and complex needs? 
• What specific interventions reduce overdose risk for people with multiple and 
complex needs and what recommendations support improvements in health, 
wellbeing and social functioning? 
• What are the gaps in knowledge and in research? 
 
This synthesis has been undertaken by the Drugs Research Network Scotland at the 
University of Stirling and we are grateful to Josh Dumbrell and Tessa Parkes for 
progressing this work. Over 50 documents were able to be included in the synthesis. 
The synthesis has enabled a number of tests of change proposals to be prepared. 
These tests of change are best viewed as a ‘suite’ of measures that a local area 
might choose to develop depending on local needs and current provision and gaps in 
services. They ideally function as part of a whole systems approach via a network of 
interconnected offerings supported by proactive collaborative working and clear 
pathways of care embedded into their respective designs. 
 
These tests of change proposed are: 
 
• A one stop shop. 
• Peer navigators, general. 
• Peer navigators, criminal justice. 
•  A drug liaison service. 
• Distress brief interventions. 
• Peer engagement and advocacy training programme. 
• Integrated mental health and substance use services. 
• Welfare advocacy. 
•  A 24-hour crisis support service/ centre. 
•  Intermediate Care Centre linking physical health care between hospital and 
the community. 
 
Priorities going forward 
It is the intention of the group to now engage with local partnerships, representative 
bodies and other interested bodies to encourage take up of funding to implement the 
tests of change. The group is aware that some areas are currently delivering these 
types of service however it is apparent that there are many gaps in service provision. 
Many areas require to develop a whole system approach to more effectively support 
people with multiple and complex needs and help reduce the incidence of drug 
related deaths. 
 
The arrangements for applying for funding and the development of evaluation 
arrangements will be concluded over the final three months of the Taskforce’s first 
year of work. Thereafter and to the end of 2020 the Multiple and Complex Needs 
Group will support Partnerships and other interested bodies to implement the tests of 
change. 
 
An essential element of success will be effective leadership from Partnerships and 






Medication Assisted Treatment 
 
Purpose  
To define national standards for the consistent delivery of ‘no barrier’ medication 
assisted treatment (MAT) in Scotland, and to help partners achieve it through a 
quality improvement approach. 
 
The term Medication Assisted Treatment (MAT) has been used to refer to the use of 
medication, such as opioids, together with psychological and social support in the 
treatment of problematic drug use. The purpose of MAT is to reduce harm, prevent 
death and support recovery.  
 
With a rights-based approach the Standards will deliver equitable, person-centered 
therapeutic treatment and care across Scotland.  
 
The initial steps for the group were as follows: 
1. Define evidence-informed standards of care 
2. Develop evidence and practice based guidance to support implementation 
3. Establish measure of success 
4. Support locally-led quality improvement approaches to implement the standards 
 
Activities in year one 
The first meetings of this sub-group focussed on the creation of work streams to 
progress particular aspects of MAT (no barrier opioid agonist treatment, 
psychosocial support and workforce development) but also discussed what these 
standards should be and how they would be consulted upon in local areas. The need 
for additional clinical expertise to be brought onto the group to provide dedicated 
quality improvement support was also agreed.  
 
The standards were developed by a small expert group, with representatives from: 
NHS Lothian; NHS Health Scotland; Scottish Drugs Forum; NHS Greater Glasgow & 
Clyde; Forth Valley Recovery Community; and NHS Tayside. These draft standards 
are: 
  
1. People have the option to start MAT from the same day of presentation. 
2. People are supported to make an informed choice on what medication to use 
for MAT and the most appropriate therapeutic dose.  
3. People (in or out of drug treatment) at high risk of drug-related harm are 
identified, prioritised, contacted and offered support to commence or continue 
MAT or other treatment. 
4. People can access evidence-based harm reduction at the point of MAT 
delivery.  
5. People receive support to remain in treatment for as long as needed.  
6. The system that provides MAT is psychologically-informed and underpinned 
by Core Behavioural and CBT Skills for Relapse Prevention and Recovery.  
7. People have the option of MAT shared with Primary Care. 
8. People have access to advocacy and support for housing, welfare and income 
needs from presentation to services. 
9. People with a dual diagnosis can receive mental health care at the point of 
MAT delivery.  





Engagement is ongoing with a range of partners for support and leadership across 
the Standards (including Lead Psychologists in Addiction Services Scotland, BBV 
Prevention Leads, Scottish Families Affected by Alcohol and Drugs, Scottish 
Recovery Consortium and the Prison Healthcare Network).  
 
Strategic visits and possible tests-of-change have also been identified for this sub-
group. This development work to support the implementation of the Standards is 
ongoing.  
 
The group has taken a person centred approach in all the work it has produced so 
far.  
 
Impact of COVID19 (March to May 2020)  
Throughout COVID-19 the Subgroup has encountered many challenges and have 
had to adapt the way of normal working:  
- staff absences due to sickness, and clinical support capacity reduced 
- Support & learning: key informants meeting established by SDF with a 
network of individuals well placed to give update on local service provision 
during the pandemic.  Reported service responses mapped against the MAT 
Standards.   
- Opportunity: Plan to follow up with areas to offer support from Operational 
Team including evidencing innovation, documenting operating procedures 
and governance arrangement across NHS Boards, share learning and where 
possible standardise approaches to meet MAT Standards. 
 
Priorities going forward 
The Subgroup has a plan of priorities going forward in stages: 
 
June 2020 to September 2020: 
The Subgroup are developing alternative virtual plans for engagement and 
consultation, to include ScotPHN Drugs Special Interest Group, Alcohol and Drug 
Partnerships, Lived experience representatives and networks and Royal colleges. 
The implementation of tests of change and ongoing quality improvement support, 
focused on standards 1-5. Partnership development for support and implementation 
(standards 6-10) is also a priority going forward, along with collating existing 
practices against the standards. 
 
September 2020 to March 2021: 
A literature review and stocktake of learning from implementation and engagement 
to date is a priority for the medium-term. Ongoing engagement and consultation, with 
a focus on the experience of those in treatment and the workforce, is also a priority. 
Rolling out learning will be ongoing. Planning for long-term inspection and oversight 
to sustain practice changes will be developed in partnership with Healthcare 







Criminal Justice and the Law  
 
Purpose 
The Scottish Government alcohol and drug strategy, ‘Rights, Respect and Recovery’ 
brought a sharper focus on requirements of the justice system to punish illegality and 
efforts to reduce harms caused by problematic drug use. In that strategy there is an 
overarching outcome that vulnerable people are diverted from the justice system 
wherever possible and those within justice settings are fully supported.  
 
The Criminal Justice and the Law Task Group has been asked to help make 
progress in two key areas to help support this outcome: 
 
(1) The Scottish Government will work with key partners to ensure that people 
who come into contact with justice agencies are provided with the right 
support from appropriate services.  A public health approach means focusing our 
community justice response on improving health and wellbeing, reducing inequalities 
and reducing crime. This means that, where appropriate, we must focus on diverting 
vulnerable people away from the justice system and into treatment and support. 
 
(2) The Scottish Government will set up a group to advise Health Ministers on 
the contribution and limitations of the Misuse of Drugs Act (1971) in support of 
health outcomes in Scotland.  Recognising that there are limitations in relation to 
public health outcomes associated with the Misuse of Drugs Act, there is a need to 
examine the links between the law, and the prevention and treatment of drug harm.  
 
The sub-group agreed to focus initially on two of the questions allocated by the Drug 
Deaths Task Force. These questions are:  
 
(1) How do we improve and accelerate access into health and social care 
services from the criminal justice system within the existing law; 
 
(2) How could changing the existing law improve this access in the event that 
the Scottish Parliament has the powers to do so? 
 
Details on membership are included in Annex A but it was drawn up with a focus on 
the first question in mind, leaving the matter of the second question for a later piece 
of work in order to preserve the independence of the Lord Advocate and Police 
Scotland.  
 
The Task Group’s membership has been augmented by those with lived experience, 
and also by SACRO, Glasgow Addictions service, and Scottish Government mental 
health and community justice colleagues. Our work to date has been supported by 
the Leading Improvement Team, and analysts from Scottish Government. We have 
met in a range of venues hosted by members of the group in most cases. 
 
Activities in Year One 
The Criminal Justice and the Law task group has had four meetings (5 November 
2019, 16 December 2019, 14 January 2020 and 7 July). Another meeting was 
scheduled for 17 March 2020, however, this meeting was postponed due to Covid-
19. In its first two meetings the group developed a process map that represented our 




possession of suspected diamorphine or benzodiazepine, to a verdict of guilty or not 
guilty in court proceedings. This approach was taken for simplicity but we recognise 
that people who use drugs can enter into the criminal justice system for a range of 
potential offences, and that often the offence does not relate to the Misuse of Drugs 
Act 1971. We also recognise that the people we are most concerned about are the 
most vulnerable habitual drug users who often have complex needs.  
 
From this process mapping, it became clear that building a shared understanding of 
the current system had been helpful in building relationships and understanding, 
perhaps challenging, pre conceptions of the processes and behaviours adopted by 
partners.  At a more practical level, a few potential areas for tests of change 
emerged, two of which we were due to begin piloting prior to the suspension of the 
group.  These tests of change are set out briefly below, although a single model that 
would allow for both of these tests to be combined is also being considered by the 
group: 
 
Parallel system of diversion  
The task group has developed an initial proposal to create a system of diversion 
running in parallel to the criminal justice pathway, information from which would be 
included in the Standard Prosecution Report to the prosecutor and could be supplied 
to the court.  
 
When the police encounter someone with illicit substances, they send the substance 
for testing and await the results, then a period of time elapses before an arrest is 
made or not. The change idea is that the police will actively divert people found in 
possession of Class A and C drugs into a process of assessment and treatment. It is 
also thought that if people can get help earlier, then the quality of the antecedent 
police report to the Procurator Fiscal will be better in respect of what people have 
engaged in, and therefore there could potentially be a higher likelihood of a case 
having a more health orientated outcome. We would track this by examining the 




Peer Navigator Model 
The group proposed to test a peer navigator model which would be introduced at the 
start of the criminal justice journey and would support those with a dependency on 
controlled substances and at risk through the process.  
 
Individuals would be given peer-delivered support, building sustained and trusting 
relationships with individual navigators who help facilitate engagement with services 
and support in navigating the criminal justice pathways from contact with the police, 
through potential time in custody and beyond. We see this as likely to be delivered in 
partnership with the police and other agencies. Again, outcomes would be tracked 
and an assessment made of its wider applicability.  
 
 
Priorities Going Forward 
The Group reconvened in June 2020 to consider how it might restart its work 




the learning across justice and health of our Covid response. This might include 
exploiting the more strongly embedded collaboration that has evolved, strengthened 
data sharing and more person centred approaches. The Group will be sensitive to 
the changes in the delivery landscape that will have emerged in this response, 
including the shift away from face to face services, and the extent to which that might 
be present for some time.  
 
In reconvening, we also wish to re- engage with the lived experience voice that has 
not, for practical reasons, been able to be as active as hoped. We are working with 
the national commissioned organisations to think afresh of how the lived and living 
experience voice can be best engaged. We would like to test our assertions about 
the criminal justice pathway with those voices, as well as our ideas for tests of 
change.  
 
Our intention was to invite local areas in regional workshops to work with the group 
to test these ideas with the potential resources available for the work of the Drug 
Death Taskforce, and be supported using improvement methodology to measure the 
impact of changes. We will be immediately reconsidering this approach in the light of 
restrictions on face to face meetings, and how we might still be able to make 
progress.  
 
The Group has already identified some further propositions for testing which can be 
further developed in its further phases and we expect those propositions to continue 
to evolve. In the longer term, we would expect the work to reach conclusions on the 
capacity of the current system to deliver health related outcome and the limitations 
on this presented by the law, and other barriers. This, then will recast the work of the 
group, and the membership to address the matter of the second question in respect 
of the opportunities presented by further devolution in this area. 
 
Other areas of interest 
There were a number of additional areas on which our thinking is less developed, 
and where there is a concern that there is duplication with existing work. These 
areas are: 
 
(1) Prisoner throughcare, on which we received a presentation from relevant 
colleagues, is an area we understand there is significant activity. This is in 
relation to both throughcare and prisoner healthcare. The group would like to 
reflect on what they have heard and will mature its thinking with a view to 
agreeing how it might add value. This reflection might now include how 
throughcare and prisoner healthcare in general may be modified following the 
Covid-19 pandemic.  
 
(2) The group were aware of the impact of the navigator model in accident and 
emergency departments, and their impact in supporting people to access 
services and begin a journey of change. We considered looking to establish if 
a specific substance service resource using this model could be helpful, but 
the existing navigator model in hospital is considered sufficient at present, and 
a new service would interfere with the natural development of the navigator 






PARTICIPATION AND A RIGHTS APPROACH TO STRENGTHENING THE DRUG 
DEATHS TASKFORCE 
 
“There is a need to recognise that the skills of individual’s are more important than 
their history (of drug taking).”  
(Source - Stirling DDTF Meeting 29-10-19) 
 
Substance use issues are associated with experiences of homelessness, poor 
mental health, poverty and involvement in justice services, highlighted by the 
findings of Hard Edges Scotland3. This report focused on the intersectional nature of 
multiple disadvantage, often including a history of domestic abuse and other 
interpersonal violence.  
 
The use of lived experience of substance use has been a consideration in the DDTF 
as part of a rights informed approach. This has occurred through taskforce 
membership, observer and sub-group liaison and through facilitated conversations at 
meetings with wider community members. These were facilitated by NHS Health 
Scotland (now Public Health Scotland), involving local and national leads in 
recovery, family support and policy leads to attempt to capture wider insights.  
 
The participative process offered was intended to work with community members 
towards enhanced accountability and opportunities for shared decision-making. It 
was led in a human rights informed way and the material generated strongly fits with 
the WHO endorsed ‘AAAQ’ framework4 that services are acceptable, accessible, 
available and of good quality. This model strongly fits with community expectations.  
 
“Human-Rights-Based-Approach for person-centred, purposeful support from 
clinician and all other services as (being)  
• enabled to ask questions and inform decisions about own care (e.g. choice 
and control in treatment options, prescription and when to come off it) 
• essential to positive relationships 
• needed to support transitions – the importance of good quality housing as 
place of safety for vulnerable individuals as an example.”  
(Source: Ayr Pre-DDTF Session 5-3-20) 
 
A fuller report on the material and recommendations gathered to date in the 
conversations with wider community members will be shared in due course but in 
summary, these are structured around three main improvement themes;  
 
1. IMPROVEMENT IN SERVICE DESIGN to increase the speed of local access 
and intervention and to deliver this in a more compassionate, person centred 
and rights-based way by: 
- Widening coverage of take home naloxone to both family and professional 
carriers 
- Improving service response in a ‘no wrong door’ policy in all public 
services  
- Improving the accuracy, timeliness and reliability of data and surveillance 
of drug deaths 
 
3 https://lankellychase.org.uk/resources/publications/hard-edges-scotland/  




- Using community expertise in training to recruit more peers and to tap into 
the wider voluntary sector  
 
2. COMMUNITY PARTICIPATION IN PREVENTING DEATHS to deliver more 
credible education and strengthen accurate prevention messages within 
communities and better use of statutory and voluntary services by:  
- Increasing the community ground level response from the bottom up 
- Increasing participation in service design and delivery as this empowers 
and reframes judgements 
- Releasing capacity in publicly owned space for activities which create 
community capital 
- Building effective trauma informed responses with the standards, 
safeguards and accountability needed.  
 
3. ADDRESSING THE DETERMINANTS OF DRUG DEATHS such as poverty, 
violence and welfare reform which are seen as missed opportunities to 
educate and intervene by:  
- A rights based response to drug deaths to build more accountable, 
collective action 
- Collaborative leadership and community activism to reduce stigma and 
oppression 
- Influencing legislation to prevent drug deaths, harms and consequences 
and build active citizenship.  
 
Continued development of broader participation and lived experience to inform the 
task force has been interrupted by the impact of Covid19. In the crisis response, 
digital exclusion has also become a threat to access and engagement in many public 
services. There has been an apparent reduction in active participation in this and a 
range of other policy areas, resulting in lost ground.  
 
Now that pandemic restrictions are lifting and the focus is on system recovery, the 
DDTF can regain this through:  
- An increase in online participation via accessible platforms for updates, 
webinars and events.  
- Widening the participation voices through a more integrated model of 
working and 
- Greater participation in creating the ‘new normal’ not the re-establishment 
of services which have been proven to be inaccessible or unacceptable to 
community members.  
 
“We need to push for things differently – how you look at the problem affects how 
you respond.  Can’t keep doing same and expect a different result.”  







DRUG DEATHS TASKFORCE – FUNDING ALLOCATION 
 
Following the creation of the DDTF, the First Minister announced in her 2019 
Programme for Government that there would be additional funding made available to 
the group to “support innovative projects, test new approaches and drive forward 
specific work to improve the quality of services”5. This commitment meant that the 
DDTF had £9 million to invest in 2020/21 and £5 million in 2021/22.  
 
Following discussions between the Chair and Vice Chair of the Taskforce, Scottish 
Government officials and the Strategic Group of the DDTF, it was decided that the 
£9 million allocated in 2020/21 would be split as follows (more information on each is 
below): 
 
• £3 million would be allocated to Scotland’s Alcohol and Drug Partnerships;  
• £5 million would be allocated to the DDTF and its sub-groups for an 
Innovation and National Developments funding programme; and 
• £1 million would be allocated to a specific research programme. 
 
Alcohol and Drug Partnership (ADP) Funding 
Scotland’s ADPs receive funding through the NHS from the Scottish Government 
each year. In addition to this year’s allocation, ADPs were made aware of additional 
money which would be made available to them (distributed between ADPs based on 
levels of drug prevalence) on submission of a proposal setting out how they would 
use this money to specifically address gaps in delivering the six evidence-based 
strategies set out by the DDTF.  
 
Bids for this additional money were to be submitted by 26 June, all 30 ADPs 
responded with applications spread across all 6 priorities. These bids were initially 
assessed by Scottish Government officials in the Alcohol, Tobacco and Drugs team 
before further assessment by a panel of DDTF members. These panel meetings took 
place in w/c 13 July.  
 
As of 31 July, £2.4 million of this fund had been allocated. Additional discussions 
were in place with a few ADPs who had submitted applications which, on review, it 
was decided required some additional information. Details of what has been funded 
through this allocation will be available on the DDTF website in due course.  
 
Innovation and National Developments Funding Programme 
This fund is open only to applications which have been sponsored or supported by 
members of the DDTF and its sub-groups and which would allow for testing of 
innovative or immediate national responses to reduce drug related deaths.  
 
Any application had to relate to work under the topics the DDTF sub-groups are 
divided into: 
• Medication Assisted Treatment 
• Public Health Surveillance 
• Criminal Justice and the Law  
 






• Multiple Complex Needs 
All applications also had to be based on the principles of the Scottish Government 
alcohol and drug strategy ‘Rights, Respect and Recovery’, and clearly demonstrate 
inclusion of co-production and consultation with people who have used services or 
have relevant lived experience. 
 
This fund is being administered on behalf of the DDTF by the Corra Foundation who 
are working with the Scottish Government Secretariat team to deliver it. Corra 
produced an application form for this fund, along with guidance notes, and made this 
available to those who had a proposal supported by one of the sub-groups.  
 
This is a rolling grant programme, with a closing date each month and a one-month 
turn-around time for assessments. The first bid for funds closed on 3 July and an 
assessment panel met to discuss those bids received on 23 July. Details of the 
successful bids from this round can be found here 
(https://drugdeathstaskforce.scot/about-the-taskforce/funding/funded-research/ ) 
 
The next round of this fund will close on 3 August with applications considered by a 
panel on 27 August. A further round will follow with applications required by 3 
September. Full details of these rounds, and those projects supported, will be 
published on the DDTF website.  
 
DDTF Research Programme 
Scottish Government analysts led on a research call seeking research proposals to 
contribute to the evidence base on interventions to reduce drug-related deaths and 
overdose, the experience of people who are most at risk and the services which 
support them.  
 
This call was issued in April 2020 with applications requested by 8 June. An 
assessment panel then met to go through the received bids and decide on 
successful applicants. The assessment panel met on 30 June and successful 
applicants were informed shortly after.  
 
Details of those research programmes which have been funded through this 






MOVING FORWARD INTO YEAR TWO 
 
We are now in the action phase of the Taskforce with funding allocated and our 
workstreams well underway.  It will take time to assess and review the impact of this 
work but we will be monitoring impact on an ongoing basis.   
 
Each project has its own built in evaluation but in addition we will be monitoring: 
• Non-fatal overdose via ambulance and emergency departments; 
• Naloxone distribution including reach into at risk populations in each health 
board area; 
• Availability of and uptake of non-fatal overdose care pathways; 
• Uptake of the MAT standards and associated measures such as % of at risk 
population in treatment, range of treatment option available, availability of 
same day prescribing and psychosocial support; 
• Ongoing surveillance of DRD and the nature and type of drugs involved. 
 
In addition we will undertake a further engagement exercise to ask stakeholders and 
affected communities what they would consider to be positive outcomes.  This will be 
built into our review and evaluation. 
 
We are currently considering accountability for implementation of our 
recommendations across workstreams.  The taskforce itself cannot deliver the 
change required and local and national leadership is essential. 
 
Finally, addressing drug related deaths in Scotland needs to be multi-faceted as the 
combination of circumstances that it has to deal with in order to succeed.  There is 
no quick fix and reversing these entrenched trends will take time.  We can only do 







DRUG DEATHS TASKFORCE AND SUB-GROUP MEMBERSHIP 
 
DDTF Members List 
Catriona Matheson – Chair 
Neil Richardson – Vice Chair  
Adam Coldwells (left May 2020) 
Ahmed Khan  
Allan Houston 
Angie Wood (joined June 2020) 
Anthony McGeehan 
Cameron Stewart  
Carey Lunan 
Carole Hunter (joined April 2020) 




Gary Ritchie ACC 
Hannah Snow (left January 2020) 
Iona Colvin 
Jason Wallace (joined July 2020) 
Jean Logan (left April 2020) 
Karyn McCluskey  
Lesley McDowall 
Michael Crook (Secretariat) 
Nicola Dickie (joined February 2020) 
Phil Mackie 
John Wood (left February 2020) 
Rebecca Wood 
Richard Watson 
Robert Peat  
Susanne Millar 




Criminal Justice and the Law  
Neil Richardson (Chair) 
Alexis Stevenson 
Anthony McGeehan 
Beverley Francis (Secretariat)  
Cameron Stewart 
Claire Miller PI 
David Doris 




Gary Ritchie ACC 











Sharon Stirrat  
William Doyle (Secretariat) 
 
Medically Assisted Treatment  
Duncan McCormick (Chair) 
Ahmed Khan  
Allan Houston 
Alison Munro  













Public Health Surveillance  
Phil Mackie (Chair) 
Alexis Stevenson 
Allan Blood 
Claire Miller PI 
Gary Ritchie ACC 
Gary Rutherford 
Lee Barnsdale 
Mark Lawson (Secretariat) 
Ryan Hughes 
Tara Shivaji  
 
Multiple and Complex Needs 
Robert Peat (Chair) 







Josh Dumbrell (left sub-group June 2020) 











Tessa Parkes (left sub-group June 2020) 
Emily Tweed (left March 2020) 
 
Participation Facilitators and Local Leads 
Elinor Dickie (Public Health Scotland) 
Phil Eaglesham (Public Health Scotland) 
Penny Mortimer (Dundee Volunteer and Voluntary Action)  
Robin Falconer (Dundee City Council)  
Tom Bennett (Forth Valley Recovery Community)   
Derek Watt (Scottish Recovery Consortium)  
David McLeod & Faye Murfet (South Ayrshire ADP)  
Rosemary Whyte (North Ayrshire ADP) 
Liam Wells (East Ayrshire ADP) 
Carolanne McLennan (Recovery Coordinator, KSRHT)  
Simon Pringle & Fraser Hoggan (Alcohol and Drugs Action Aberdeen)  
Jason Wallace (Glasgow City Centre Users Group)  
Gillian Ferguson (Glasgow Engagement Group)  
Austin Smith (DSF)  
 
Along with advice from DDTF members/observers – Becky Wood, Justina Murray, 
















DDTF and Subgroup Meetings to date & upcoming: 
 
NAME OF MEETING/GROUP  
 




Drug Death Taskforce Meeting 
 
17th September 2019 
 
Quaker meeting house, Edinburgh 
 
Drug Death Taskforce Meeting 
 
29th October 2019 
 
Stirling Highland House, Stirling  
 
Drug Death Taskforce Meeting 
 
15th January 2020 
 
Cairn Centre, Dundee 
 
Drug Death Taskforce Meeting 
 
8th April 2020 
 
Virtual meeting via Zoom 
 
Drug Death Taskforce Meeting 
 
13th May 2020 
 
Virtual meeting via Zoom 
 
Drug Death Taskforce Meeting 
 
18th June 2020 
 
Virtual meeting via Zoom 
 
Drug Death Taskforce Meeting 
 
24th July 2020 
 
Virtual meeting via Zoom 
 
Drug Death Taskforce Meeting 
 
2nd September 2020 
 
Virtual meeting via Zoom 
 
Drug Death Taskforce Meeting 
 
7th October 2020 
 
Virtual meeting via Zoom 
 
Sub Group : Medically Assisted Treatment  
 
18th March 2020 
 





Sub Group : Medically Assisted Treatment 
 
23rd April 2020 
 
Virtual meeting via Zoom 
 
Sub Group : Medically Assisted Treatment 
 
24th June 2020 
 
Virtual meeting via Zoom 
 
Sub Group : Criminal Justice and the Law 
 
5th November 2019 
 
Scottish Youth Centre, Glasgow 
 
Sub Group : Criminal Justice and the Law 
 
10th December 2019 
 
Scottish Prison Service College, Falkirk 
 
Sub Group : Criminal Justice and the Law 
 
14th January 2020 
 
New Register House Dome Seminar 
Facility, Edinburgh 
 
Sub Group : Criminal Justice and the Law 
 
7th July 2020 
 
Virtual meeting via Zoom 
 
Sub Group : Multiple Complex Needs 
 




Sub Group: Multiple Complex Needs 
 




Sub Group: Multiple Complex Needs 
 




Sub Group: Multiple Complex Needs 
 
15th January 2020 
 
Cairn Centre, Dundee 
 
Sub Group: Multiple Complex Needs 
 
5th February 2020 
 
St Andrews House, Edinburgh 
 
Sub Group: Multiple Complex Needs 
 




Sub Group: Multiple Complex Needs 
 
23rd April 2020 
 





Sub Group: Multiple Complex Needs 
 
18th May 2020 
 
Virtual meeting via Zoom  
 
Sub Group: Multiple Complex Needs 
 
11th June 2020 
 
Virtual meeting via Zoom 
 
Sub Group: Multiple Complex Needs 
 
2nd July 2020 
 
Virtual meeting via Zoom 
 
Sub Group: Multiple Complex Needs 
 
27th July 2020 
 
Virtual meeting via Zoom 
 
Sub Group: Multiple Complex Needs 
 
24th August 2020 
 
Virtual meeting via Zoom 
 
Sub Group: Multiple Complex Needs 
 
14th September 2020 
 
Virtual meeting via Zoom 
 
Sub Group: Multiple Complex Needs 
 
15th October 2020 
 
Virtual meeting via Zoom 
 
Sub Group: Multiple Complex Needs 
 
12th November 2020 
 
Virtual meeting via Zoom 
 
Sub Group: Multiple Complex Needs 
 
4th December 2020 
 
Virtual meeting via Zoom 
 






Sub Group: Public Health Surveillance  
 




Sub Group: Public Health Surveillance 
 




Sub Group: Public Health Surveillance 
 









The Criminal Justice and the Law sub-group has undertaken a programme of visits to provide members with the opportunity to 
examine first-hand evidence. Visits were organised to: 
• Durham Constabulary’s diversion scheme Checkpoint 
• Glasgow’s Drug Court 
• Thames Valley Police Drugs Diversion Pilot Scheme.  
 
A visit had also been scheduled to HMP Perth however this had been due to occur on 26 March 2020 and was cancelled following 
the introduction of lockdown. This may be rescheduled, or we may look into alternative opportunities for similar learning 
 
